查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870575

抗血栓药物市场按药物类别、适应症、给药途径和最终用户划分－2025-2032年全球预测

Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗血栓药物市场规模将达到 688.5 亿美元，年复合成长率为 6.22%。

关键市场统计数据
基准年 2024 424.7亿美元
预计年份：2025年 451.5亿美元
预测年份 2032 688.5亿美元
复合年增长率 (%) 6.22%

明确阐述抗血栓治疗的类型、其临床意义以及影响临床实务中治疗决策的策略要务。

抗血栓治疗涉及急诊、慢性病管理和预防心臟病学等多个领域，对多种心血管和血栓性栓塞症的发生和发展产生影响。近年来，治疗技术的进步促使临床实践转向使用具有可预测药物动力学的口服直接抗血栓药物，但在手术全期和急诊住院环境中，肠外给药仍然至关重要。本文建构了一个框架，阐述了抗血栓治疗的治疗分类、临床适应症和实践环境，从而指导目前的抗血栓治疗决策。

临床实践、商业化模式、监管监督和数位医疗服务的重大转变正在重新定义抗血栓策略和供应动态。

抗血栓治疗领域正经历一系列交织的变革，这些变革正在重塑临床实践、商业模式和供应链结构。口服直接抗凝血剂的进步，透过提供固定剂量方案和减少监测需求，促进了部分传统疗法的临床转化。然而，医院的通讯协定仍依赖肠外肝素进行急性期治疗和手术全期期过渡。同时，基于肾功能评估、药物交互作用意识增强以及逆转剂选择范围扩大而日益重视的个人化治疗，也使得临床医师教育和决策支援工具的重要性日益凸显。

分析近期关税政策变化如何影响抗血栓治疗价值链的采购、生产选择、供应和长期供应韧性。

美国在2010年代中期推出的关税措施和贸易政策转变产生了累积影响，波及抗血栓疗法的采购、生产和下游分销。依赖跨国活性原料药（API）和辅料的製造商，即使核心成分的关税有限，也因关税分类变更及相关行政程序而面临采购成本和前置作业时间的影响。实际上，这些调整增加了某些产品成分的到岸成本，并加剧了对单一供应来源的依赖。

透过深度細項分析，将治疗领域、临床适应症、给药途径和终端用户管道连结起来，从而製定有针对性的临床和商业策略。

严谨的市场区隔分析阐明了产品属性、临床适应症、给药途径和终端使用者环境如何相互作用，从而影响药物的采纳和使用。从药物类别观点，市场可分为抗凝血剂、抗血小板药物和溶栓剂，其中抗凝血剂可细分为直接口服抗凝血剂（DOAC）、肝素和维生素K拮抗剂。在直接口服抗凝血剂中，市场可分为直接凝血酶抑制剂和Xa因子抑制剂，前者以Dabigatran为代表，后者以Apixaban、艾多沙班和Rivaroxaban为代表。肝素製剂分为低分子肝素和未分级肝素，二者各自发挥不同的临床功效。

美洲、欧洲、中东和非洲以及亚太地区的区域法规结构、采购规范和医疗服务路径如何驱动差异化的招募和供应策略

区域趋势对全球抗血栓治疗领域的临床实务模式、管理体制、製造地和支付方策略均有显着影响。在美洲，成熟的医保报销体系和口服直接抗凝血剂的广泛应用正推动许多慢性疾病的治疗模式向门诊管理转变，而医院系统在急性肠外给药疗法的采购方面仍然拥有强大的影响力。该地区的监管流程高度重视上市后监测和真实世界数据的收集，这有望加速新型药物的医疗保险谈判和基本契约。

策略竞争格局受产品系列广度、真实世界数据 (RWE) 的产生、供应伙伴关係附加价值服务的影响。

抗血栓治疗领域的竞争动态反映了口服直接作用药物的创新、肠外肝素的持续重要性以及抗血小板和溶栓疗法在急性期治疗中的长期作用之间的平衡。拥有涵盖口服和注射的多元化产品系列的公司可以利用与医院、零售药局和居家医疗机构的跨通路合作关係，在整个医疗保健领域保持市场份额。对真实世界数据、药物监测和病患援助计画的策略性投资已成为影响药品目录定位和医师处方偏好的关键差异化因素。

实现竞争优势的可操作策略重点：证据完整性、供应弹性、通路客製化、数位化应用与支付方协作

为维持竞争优势，产业领导者应优先考虑整合策略，兼顾临床价值、供应链韧性和通路特定交付。首先，应协调进行实证项目，在最相关的适应症中，于真实世界环境中验证疗效和安全性，确保数据能够支持与支付方、医院处方集委员会和临床医生团体的对话。其次，应透过原材料来源多元化、在可用地区建立生产能力以及建立二级供应商和紧急物流能力来降低供应链脆弱性，从而防止口服和注射产品的供应中断。

采用透明的混合方法，结合专家访谈、监管和临床文献的综合分析以及迭代式细分检验，确保获得可操作的洞见。

本报告的研究结合了定性和定量证据，以确保对研究结果进行可靠的三角验证。主要研究包括对临床意见领袖、采购人员、医院药剂师和专科药品分销商进行结构化访谈，以了解住院和门诊护理环境中的营运实践和决策驱动因素。此外，也咨询了生产专家和监管事务负责人，以梳理供应链的限制和合规要求。

企业必须整合临床、商业性和营运方面的必要因素，才能实现持续的治疗价值和可靠的病患用药途径。

抗血栓治疗管理的特点是临床创新不断涌现，同时营运和市场也持续复杂。口服直接作用药物和注射用肝素的平衡、从慢性预防到急性干预的广泛适应症，以及这些疗法在各种医疗机构中的应用，共同构成了一个需要兼顾临床价值、可靠供应和渠道匹配服务的复杂局面。因此，决策者面临双重挑战：他们必须证明其治疗方案具有差异化的临床疗效，同时确保其生产、分销和支付方参与策略同样稳健有效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大Xa因子抑制剂的应用范围，包括周边动脉疾病和支架置入术后血栓症形成预防。
  • 一种新型口服直接凝血酶抑制剂对心房颤动病人用药依从性的影响
  • 引入精准医疗方法，以基于药物基因组学分析实现个人化抗血栓治疗
  • 生物类似低分子量肝素的竞争加剧，导致医院采购价格下降。
  • 整合数位化健康监测解决方案，实现抗凝血治疗的即时管理和剂量调整
  • 开发一种新型口服抗凝血剂的可逆解毒剂，可降低紧急情况下的出血风险。
  • 在患有高风险心血管疾病的患者中，双通路抑制剂疗法（低剂量抗凝血剂和抗血小板药物联合使用）的应用日益增多
  • 正在扩大临床试验计画线，研究新型因子XI和因子XII抑制剂，旨在降低出血风险。
  • 监管改革将加快突破性抗血栓疗法的审批流程，以满足中风预防方面尚未满足的需求。
  • 长效皮下抗凝血剂製剂的市场渗透率不断提高，使得慢性病患者能够减少给药频率。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗血栓药物市场（依药物类别划分）

  • 抗凝血剂
    • 直接口服抗凝血剂
      • 直接凝血酶抑制剂
      • Dabigatran
      • Xa因子抑制剂
      • Apixaban
      • 艾多沙班
      • Rivaroxaban
    • 肝素
      • 低分子量肝素
      • 未分级肝素
    • 维生素K拮抗剂
  • 抗血小板药物
  • 溶栓药物

第九章 依适应症分類的抗血栓药物市场

  • 心房颤动
  • 深层静脉栓塞症
  • 心肌梗塞
  • 肺动脉栓塞
  • 预防中风

第十章 按给药途径分類的抗血栓药物市场

  • 口服
    • 药片
  • 肠外
    • 注射

第十一章 按最终用户分類的抗血栓药物市场

  • 居家医疗
  • 医院
  • 零售药房

第十二章：各地区抗血栓药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 抗血栓药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国抗血栓药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bayer Aktiengesellschaft
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • AstraZeneca PLC
    • Johnson & Johnson
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Novartis AG
    • Merck & Co., Inc.
Product Code: MRR-1A1A064C01CD

The Antithrombotic Drugs Market is projected to grow by USD 68.85 billion at a CAGR of 6.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 42.47 billion
Estimated Year [2025] USD 45.15 billion
Forecast Year [2032] USD 68.85 billion
CAGR (%) 6.22%

A clear orientation to antithrombotic therapy classes, clinical relevance, and the strategic imperatives shaping therapeutic decision-making across care settings

Antithrombotic therapies sit at the intersection of acute care, chronic disease management, and preventative cardiology, influencing outcomes across a broad spectrum of cardiovascular and thromboembolic conditions. Recent therapeutic progress has rebalanced clinical practice toward oral direct agents with predictable pharmacokinetics, while parenteral options remain essential in perioperative and acute hospital contexts. This introduction frames the therapeutic classes, clinical indications, and care settings that define contemporary decision-making in antithrombotic management.

Clinicians now weigh efficacy, safety, patient adherence, renal and hepatic considerations, and reversal strategies when selecting agents for conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke prevention. At the same time, health systems and payers evaluate total cost of care, real-world safety signals, and patient-centric delivery models, including home-based therapies and outpatient monitoring. This dynamic landscape demands integrated evidence synthesis that connects pharmacology, clinical pathways, and operational feasibility.

The remainder of this executive summary lays out transformative shifts in the therapeutic and commercial environment, examines external policy pressures such as tariff activity and supply-chain risks, and surfaces segmentation, regional, and competitive insights. Together these sections equip leaders to refine portfolio priorities, optimize distribution strategies, and align clinical value propositions with evolving payer and provider expectations.

Critical shifts in clinical practice, commercialization models, regulatory scrutiny, and digital care delivery that are redefining antithrombotic strategy and supply dynamics

The antithrombotic landscape is undergoing a set of convergent transformations that are reshaping clinical practice, commercial models, and supply-chain architecture. Advances in oral direct anticoagulants have driven a clinical pivot away from some legacy therapies by offering fixed dosing regimens and fewer monitoring requirements, yet hospital protocols continue to rely on parenteral heparins for acute management and perioperative bridging. Simultaneously, heightened emphasis on individualized therapy-driven by renal function assessment, drug-drug interaction awareness, and an expanding armamentarium of reversal agents-has elevated the importance of clinician education and decision-support tools.

On the commercial front, payers and health systems are intensifying scrutiny of total cost of ownership and real-world outcomes, prompting manufacturers to demonstrate tangible value through outcomes studies, patient support programs, and novel contracting approaches. Parallel to these forces, digital health solutions and remote monitoring are extending the continuum of care beyond traditional clinic walls, enabling safer outpatient management of chronic anticoagulation and earlier identification of adverse events. These technology-enabled care models are also catalyzing greater engagement from retail pharmacies and home-care providers in medication management and adherence initiatives.

Regulatory and quality expectations are tightening around pharmacovigilance and supply-chain transparency, while manufacturing innovations aim to reduce batch variability and improve accessibility of injectable and oral formulations. Together, these shifts require cross-functional preparedness-from clinical affairs and regulatory teams to manufacturing and commercial operations-to capture new opportunities and mitigate emerging risks.

Analysis of how recent tariff policy shifts influenced sourcing, manufacturing choices, inventory posture, and long-term supply resilience across antithrombotic value chains

Recent tariff measures and trade policy shifts introduced by the United States in the mid-decade window created a cumulative set of effects that ripple across sourcing, manufacturing, and downstream distribution for antithrombotic therapies. Manufacturers that rely on cross-border APIs and excipients saw procurement costs and lead times influenced by tariff classification changes and associated administrative duties, even when core ingredient tariffs were limited. In practice, these adjustments translated into higher landed costs for certain product components and heightened sensitivity to single-source dependencies.

In response, several supply-chain strategies have emerged. Manufacturers accelerated supplier diversification, reshored or near-shored critical stages of production, and expanded validated secondary suppliers to preserve continuity for both oral and parenteral formulations. Contract manufacturers and distributors revised procurement terms to incorporate tariff pass-through clauses, and procurement teams increased the frequency of scenario planning to model tariff-driven cost variability. Health systems and large pharmacy chains responded by tightening inventory management protocols and expanding safety stock levels for essential injectables and oral agents to avoid disruption in acute care pathways.

Regulatory compliance and customs clearance processes also became more prominent operational considerations. Firms invested in tariff classification expertise and enhanced documentation to reduce delays at ports of entry. While tariffs themselves were one element, their broader cumulative impact was to incentivize structural changes across supply networks, encouraging regional manufacturing footprints and more resilient logistics arrangements. These adaptations reduced short-term fragility but have long-term implications for unit economics, strategic sourcing, and the geographic distribution of manufacturing capacity.

Deep segmentation analysis connecting therapeutic classes, clinical indications, administration routes, and end-user channels to inform targeted clinical and commercial strategies

A rigorous segmentation lens clarifies how product attributes, clinical indications, administration routes, and end-user contexts interact to shape adoption and utilization. From a drug class perspective, the market environment is parsed across anticoagulants, antiplatelets, and thrombolytics, with the anticoagulant subset further differentiated into direct oral anticoagulants, heparins, and vitamin K antagonists. Within direct oral anticoagulants, the landscape separates direct thrombin inhibitors and factor Xa inhibitors, with dabigatran exemplifying the former and apixaban, edoxaban, and rivaroxaban representing the latter group. Heparins remain differentiated by low molecular weight formulations versus unfractionated heparin, each maintaining distinct clinical roles.

When viewed through the lens of clinical indication, therapeutic selection is influenced by characteristic risk profiles and care pathways associated with atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, and stroke prevention. Route of administration introduces further nuance: oral formulations, primarily tablets, offer adherence advantages and outpatient convenience, while parenteral options administered by injection remain central to acute management and perioperative strategies. Finally, end-user segmentation highlights divergent distribution and support requirements across home care, hospital, and retail pharmacy settings, with each channel presenting different demands for education, monitoring, and inventory management.

Overlaying these segmentation dimensions reveals practical implications for lifecycle management, clinical positioning, and commercial deployment. For example, products targeting chronic atrial fibrillation benefit from investments in adherence support and prescriber education relevant to outpatient care, whereas agents primarily used in acute pulmonary embolism or perioperative bridging require robust hospital supply assurance and clinical protocols to secure formulary adoption. Understanding these intersecting segmentation vectors enables tailored go-to-market approaches and more precise alignment of clinical evidence with channel-specific value propositions.

How regional regulatory frameworks, procurement norms, and care pathways across the Americas, Europe Middle East and Africa, and Asia Pacific drive differentiated adoption and supply strategies

Regional dynamics significantly influence clinical practice patterns, regulatory regimes, manufacturing footprints, and payer approaches across the global antithrombotic landscape. In the Americas, a mature reimbursement environment and widespread adoption of oral direct agents have shifted care models toward outpatient management for many chronic indications, while hospital systems maintain strong purchasing leverage for acute parenteral therapies. Regulatory pathways in the region emphasize post-market surveillance and real-world evidence generation, which tends to accelerate formulary dialogue and outcomes-based contracting for newer agents.

Across Europe, the Middle East & Africa, regulatory heterogeneity creates differentiated market access paths and local procurement norms, prompting manufacturers to tailor pricing, evidence, and supply strategies by jurisdiction. Centralized procurement in some territories and fragmented payer landscapes in others mean that product positioning must align with localized health economics arguments, particularly where generics and established injectables compete on cost and availability. Moreover, capacity constraints and logistic complexity in certain markets within this region heighten the importance of regional manufacturing and distribution partnerships.

The Asia-Pacific region combines rapid clinical adoption in certain high-income markets with capacity-driven opportunities in emerging economies. Rapid urbanization, expanding hospital networks, and increasing chronic disease prevalence drive demand for both oral and parenteral solutions, while regional manufacturing hubs and contract production facilities offer strategic options for cost-effective supply. Across all regions, interoperability of clinical guidelines, availability of reversal agents, and the maturity of outpatient care pathways influence the pace and nature of therapeutic uptake.

Strategic competitive patterns shaped by portfolio breadth, real-world evidence generation, supply partnerships, and value-added services that influence prescriber and payer decisions

Competitive dynamics in the antithrombotic arena reflect a balance between innovation in oral direct agents, ongoing relevance of parenteral heparins, and the enduring role of antiplatelet therapies and thrombolytics in acute settings. Companies with diversified portfolios across oral and injectable forms can leverage cross-channel relationships with hospitals, retail pharmacies, and home-care providers to sustain presence across the continuum of care. Strategic investments in real-world evidence, pharmacovigilance, and patient support programs have become critical differentiators that influence formulary positioning and prescriber preference.

Business models are adapting through greater emphasis on lifecycle management-extending indications, supporting comparative effectiveness studies, and ensuring access to reversal agents and monitoring tools. Partnerships and licensing arrangements between originators and regional manufacturers enable broader geographic coverage while preserving supply chain flexibility. Contract manufacturing organizations play a pivotal role in scaling injectable production, prompting companies to secure long-term capacity agreements and co-invest in quality assurance mechanisms to mitigate lot-to-lot variability.

Mergers, acquisitions, and strategic alliances continue to be levers for acquiring complementary capabilities, such as digital adherence platforms, specialty distribution networks, and clinical trial capacity. Firms that can integrate clinical evidence generation with robust supply assurance and channel-tailored services will be better positioned to maintain durable clinician and patient trust in a competitive therapeutic field.

Actionable strategic priorities focused on evidence alignment, supply resilience, channel customization, digital enablement, and payer collaboration to secure competitive advantage

Industry leaders should prioritize integrated strategies that address clinical value, supply resilience, and channel-specific delivery to maintain competitive advantage. First, align evidence-generation programs to demonstrate comparative clinical outcomes and safety in real-world settings for the most relevant indications, ensuring that data supports conversations with payers, hospital formulary committees, and clinician groups. Second, reduce supply-chain vulnerability by diversifying raw material sources, establishing regional manufacturing capacity where feasible, and formalizing secondary suppliers and contingency logistics to prevent service interruptions for both oral and injectable products.

Third, tailor commercial approaches to end-user contexts: invest in adherence and education programs for outpatient tablets, while ensuring rapid-response logistics, clinician training, and hospital formulary support for parenteral agents. Fourth, leverage digital health tools to support remote monitoring, dosing decision support, and patient engagement to improve adherence and reduce adverse events. Fifth, pursue collaborative contracting and risk-sharing arrangements with payers and health systems that align payments with measurable patient outcomes and real-world safety profiles.

Finally, integrate regulatory intelligence and tariff risk assessment into strategic planning to anticipate policy changes that could affect input costs and distribution timelines. By coordinating clinical, commercial, regulatory, and supply-chain initiatives, companies can create defensible positioning and responsive operational structures that support sustainable growth in a complex global market.

Transparent mixed-methods approach combining expert interviews, regulatory and clinical literature synthesis, and iterative segmentation validation to ensure actionable insights

The research underpinning this report combined qualitative and quantitative evidence streams to ensure robust, triangulated insights. Primary research included structured interviews with clinical thought leaders, procurement executives, hospital pharmacists, and specialty distributors to capture operational realities and decision drivers across inpatient and outpatient care settings. These engagements were complemented by consultations with manufacturing experts and regulatory affairs professionals to map supply-chain constraints and compliance imperatives.

Secondary research synthesized regulatory guidance, clinical trial publications, pharmacovigilance reports, and publicly available formulary determinations to contextualize primary findings and validate thematic trends. Data synthesis relied on careful cross-referencing across sources to minimize bias and to ensure that conclusions reflected consistent signals rather than isolated observations. The segmentation framework was applied iteratively, testing assumptions across drug class, indication, route of administration, and end-user scenarios to validate strategic implications.

Quality assurance protocols included peer review by domain experts and internal consistency checks to reconcile differences between stakeholder perspectives. The methodological approach emphasized transparency, reproducibility, and relevance to commercial and clinical decision-making, enabling practitioners to translate insights into tactical and strategic initiatives.

Synthesis of clinical, commercial, and operational imperatives that companies must align to deliver sustained therapeutic value and dependable access for patients

Antithrombotic therapy management is characterized by steady clinical innovation coupled with persistent operational and market complexity. The balance between oral direct agents and parenteral heparins, the multifaceted indications spanning chronic prevention to acute intervention, and the diverse care settings that deliver these therapies create a landscape in which clinical value must be matched by dependable supply and channel-aligned services. Decision-makers therefore face a dual imperative: demonstrate differentiated clinical outcomes while ensuring that manufacturing, distribution, and payer engagement strategies are equally robust.

Looking forward, organizations that integrate rigorous evidence programs with resilient supply architectures and targeted customer engagement will be best positioned to navigate regulatory shifts, tariff-driven cost pressures, and evolving care delivery models. Operational foresight-manifested in supplier diversification, regional manufacturing, and digital-enabled care pathways-will reduce exposure to external shocks while supporting sustainable access for patients. In sum, successful strategies will be those that holistically align clinical differentiation with pragmatic execution across the full product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of Factor Xa inhibitors in expanding indications such as peripheral artery disease and post-stent thrombosis prevention
  • 5.2. Impact of emerging direct thrombin inhibitors with oral formulations on patient adherence in atrial fibrillation
  • 5.3. Adoption of precision medicine approaches to tailor antithrombotic therapy based on pharmacogenomic profiling
  • 5.4. Increased competition from biosimilar low molecular weight heparins driving price erosion in hospital procurement
  • 5.5. Integration of digital health monitoring solutions for real-time anticoagulation management and dosing adjustments
  • 5.6. Development of reversible antidotes for novel oral anticoagulants to mitigate bleeding risk in emergency settings
  • 5.7. Rising use of dual pathway inhibition regimens combining low-dose anticoagulants with antiplatelet agents in high-risk cardiovascular patients
  • 5.8. Expansion of clinical trial pipelines investigating novel factor XI and XII inhibitors for lower bleeding risk profiles
  • 5.9. Regulatory shifts favoring expedited review pathways for breakthrough antithrombotic therapies to address unmet stroke prevention needs
  • 5.10. Growing market penetration of long-acting subcutaneous anticoagulant formulations enabling reduced dosing frequency in chronic care settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombotic Drugs Market, by Drug Class

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
      • 8.1.1.1. Direct Thrombin Inhibitors
      • 8.1.1.1.1. Dabigatran
      • 8.1.1.2. Factor Xa Inhibitors
      • 8.1.1.2.1. Apixaban
      • 8.1.1.2.2. Edoxaban
      • 8.1.1.2.3. Rivaroxaban
    • 8.1.2. Heparins
      • 8.1.2.1. Low Molecular Weight Heparin
      • 8.1.2.2. Unfractionated Heparin
    • 8.1.3. Vitamin K Antagonists
  • 8.2. Antiplatelets
  • 8.3. Thrombolytics

9. Antithrombotic Drugs Market, by Indication

  • 9.1. Atrial Fibrillation
  • 9.2. Deep Vein Thrombosis
  • 9.3. Myocardial Infarction
  • 9.4. Pulmonary Embolism
  • 9.5. Stroke Prevention

10. Antithrombotic Drugs Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Tablet
  • 10.2. Parenteral
    • 10.2.1. Injection

11. Antithrombotic Drugs Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Retail Pharmacy

12. Antithrombotic Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antithrombotic Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antithrombotic Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer Aktiengesellschaft
    • 15.3.2. Pfizer Inc.
    • 15.3.3. Bristol-Myers Squibb Company
    • 15.3.4. Sanofi S.A.
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Johnson & Johnson
    • 15.3.7. Boehringer Ingelheim International GmbH
    • 15.3.8. Daiichi Sankyo Company, Limited
    • 15.3.9. Novartis AG
    • 15.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ANTITHROMBOTIC D